Shorla Pharma, an Irish specialty pharmaceutical company, completed an $8.3m Series A financing.
The round was led by Seroba Life Sciences with participation from Irish and Canadian based family offices and participation from Enterprise Ireland. In conjunction with the funding, Alan O’Connell, a Partner at Seroba, has joined the Shorla board.
The funding will support the advancement of the product pipeline, along with expansion of technical and commercial operations in both Ireland and the US.
Established by Sharon Cunningham and Orlaith Ryan in 2018, both formerly with EirGen Pharma in Waterford, Ireland, Shorla has developed innovative oncology drugs with a focus on rare, orphan and pediatric cancers. Shorla is based in Questum, a Clonmel, Ireland based acceleration center.
FinSMEs
03/06/2020